We need you! See something you could improve? Make an edit and help improve WikSM for everyone.

Osteoarthritis

From WikiSM
Jump to: navigation, search

Contents

Other Names

  • Arthritis
  • Arthur
  • Osteoarthritis (OA)
  • “wear-and-tear” arthritis
  • Age-related Arthritis
  • Degenerative Joint Disease (DJD)
  • Degenerative Arthritis

Background

Definition

  • Radiographic
    • Presence of a definite osteophyte (Grade ≥2 on kellgren-lawren classification)[1]
    • More severe grades by the presumed successive appearance of joint space narrowing, sclerosis, cysts, and deformity
    • Note, MRI is more sensitive for soft tissue changes but not required for diagnosis
  • Clinical
    • Generally defined as presence of pain, aching or stiffness with radiographic findings consistent with OA
    • Not all patients with joint symptoms have radiographic OA[2]
    • Not all patients with radiographic OA have clinical disease

Epidemiology

  • General
    • Most common joint disease in the world
    • Statistics vary somewhat depending on definition of OA being used
    • Murphy et al estimated estimated the lifetime risk of developing symptomatic knee OA to be 40% in men and 47% in women[3]
    • In 2017, affected 303 million people globally[4]
  • Prevalence
    • Affects 10% of men, 18% of women over 60 years of age[5]
    • Framingham study: prevalence was 19.2% among participants over 45[6]
    • Johnston County Osteoarthritis Project: prevalence was 27.8% among participants over 45
    • NHANES III: 37% of patients over 60 had radiographic evidence of knee OA
  • Incidence
    • Hip OA: 88 per 100,000 person-years[7]
    • Knee OA: 240 per 100,000 person-years
    • Hand OA: 100 per 100,000 person-years

Economic Burden

  • In developed countries, estimated to cost between 1 - 2.5% of GDP[8]
  • Arthritis is responsible for more disability in the US workforce than any other factor[9]
  • Approximately 21.6% of US adults (46.4 million) reported physician-diagnosed arthritis in 2005[10]
    • This number is projected to skyrocket by 40% to nearly 67 million by 2030
  • 2004: Arthritis drained approximately $281.5 billion from the US economy, an increase of 53% from 1996[11]

Pathophysiology

Cartilage

  • Type II collagen most important structural protein
  • Chondrocytes regulate cartilage architecture, biomechanical composition
  • When activated, chondrcytes release multiple inflammatory cytokines including TNF-alpha, IL-6, IL-1, metalloproteinases, disintegrin
  • In osteoarthritis, the immune system is activated by damage-associated molecules including glycosaminoglycans, hyaluronon[12]
  • Calcium pyrophysphate and sodium urate crystals also bind to chondrocytes
  • It is unclear if chondrocytes are primarily activated from cartilage degredation or secondarily from other joint structures

Subchondral Bone

  • Forms anchor between articular cartilage and trabecular bone
  • Osteoblasts respond to mechanical stimulation similar to chondrycytes[13]
  • Pronounced changes occur in subchondral bone in osteoarthritis[14]
  • Radiographs evidence includes osteophytes, subchondral cysts, subchondral sclerosis
  • MRI can also demonstrate microfractures at different stages of healing[15]
  • One study suggested that subchondral degeneration may precede cartilage degeneration[16]
  • Subchondral bone is highly innervated and contributes to pain generation[17]

Synovium

  • Inflammation of the synovium, termed synovitis, is a commonly seen in osteoarthritis
  • Synoviocytes are noted to proliferate under arthritic stress, producing hyaluronic acid and lubricin[18]
  • In physiologically normal patients, these proteins provide lubrication and reduced stress load
  • In patients with osteoarthritis, they demonstrate reduced lubrication and stress reduction[19]
  • Synoviocytes also release inflammatory markers similar to osteoblasts and chondroblasts

Systemic Inflammation

  • In general, osteoarthritis is considered a localized pathologic state and not a systemic illness
  • 2013 systematic review: C-reactive associated with symptoms but not radiographic findings[20]

Risk Factors

General

  • Age (#1 Risk Factor)[21]
  • Women > Men
    • More likely to have OA[22]
    • OA is more severe in women
  • Estrogen
    • Conflicting results, regardless of whether endogenenous or exogenous[23]
  • Race
    • Less common in Chinese than white[24]
    • African Women (23%) similar to white women (22%); African men (21%) higher than white men (17%)[25]
  • Trauma
  • Genetics
    • Twin studies estimate the heritable component of OA to be between 50% - 65%[26]
  • Injuries
  • Occupation
    • Repetitive labor
    • Occupations that require carrying, kneeling, squatting
  • Sports
    • Studies have produced conflicting results
    • Physical Activity: High life time physical activity associated with knee OA[29] and hip OA[30]
    • Long Distance Runners: Hip OA[31], Knee OA[32]
    • Soccer Players: Knee OA[33]

Medical Conditions

  • Obesity
    • Most notable for hip and knee[34]
    • Weight loss associated with reduction in risk[35]
  • Gout

Diet & Nutrition

  • Vitamin D
    • Overall, mixed results
    • Low vitamin D associated with increased risk of progression of knee OA compared to individuals with higher vitamin D [36]
    • Serum vitamin D levels were not associated with the risk of hip OA[37]
    • 2 cohort studies failed to confirm any protective effect of vitamin D supplementation on the structural worsening of knee OA[38]
  • Vitamin C
    • Low vitamin C dietary intake was associated with an increased risk of progression, but not incidence, of both radiographic and symptomatic knee OA[39]
  • Vitamin E
    • Supplementation with vitamin E failed to ameliorate symptoms in patients who had symptomatic knee OA or to prevent knee OA progression[40]
  • Selenium
    • Animal studies: low selenium associated with irregular bone formation, decreased bone strength, and abnormalities in type I and II collage in cartilage[41]
    • China: Low selenium associated with increased risk of kashin-beck disease, a form of arthritis, and risk was reduced with selenium supplementation[42]
    • Another study found high selenium intake was significantly associated with increased risk of both hip and knee OA[43]
  • Vitamin K
    • Neogi et al: Low vitamin K associated with osteoarthritis of the hand and knee[44]

Hand

  • Dominick et al: inverse association between grip strength and carpometacarpal OA; between pinch strength and metacarpophalangeal OA[45]
  • Framingham study: Increased grip strength associated with increased risk of hand OA[46]

Hip

Knee


List of Osteoarthropathies

Upper Extremity

Torso

  • Needs to be updated

Lower Extremity


Clinical Features

  • Symptoms that correlate with radiographic findings and no other clear etiology
  • Most patients report a painful range of motion; range of motion often decreased
  • Most patients report pain in the affected joint, worse with activity or use of the affected limb
  • In weight bearing joints, ambulation, stairs and activity typically make it worse
  • Patients may endorse swelling, deformity, crepitus

Evaluation

  • Radiographs
    • 3 View radiograph of affected joint is standard
    • Radiographic features:
      • Loss of the joint space width (sensitive, not specific)[51]
      • Osteophyte formation
      • Subchondral sclerosis and cysts
  • MRI
    • More sensitive for early osteoarthritis changes as it better evaluates soft tissue abnormalities[52]
    • Cartilage morphology predicts disease progression (population level only)[53]
    • Scoring systems exist for knee, hip and hand
  • Ultrasound
    • Gaining popularity as a diagnostic modality[54]
    • Can assess synovium
  • CT
    • Not a significant role in the evaluation of suspected osteoarthritis

Classification

Kellgren and Lawrence (KL) Classification

  • Originally proposed for classifying knee OA, now more broadly applied to all joints
  • Grade 0: no radiographic features of OA present
  • Grade 1: doubtful joint space narrowing, possible osteophytic lipping
  • Grade 2: definite osteophytes, possible joint space narrowing on anteroposterior weight-bearing radiograph
  • Grade 3: multiple osteophytes, definite joint space narrowing, sclerosis, possible bony deformity
  • Grade 4: large osteophytes, marked joint space narrowing, severe sclerosis and definite bony deformity

Management

Lifestyle Modification

Weight Loss

  • In obese patients without osteoarthritis, weight loss reduces the risk of developing osteoarthritis[55]
  • In obese patients with osteoarthritis, weight loss improves symptoms of disease[56]
  • Weight loss was associated with increased type II collagen (cartilage synthesis) and decrease cartilage oligomeric matrix protein, a biomarker of cartilage degredation. These changes also correlated with reduced insulin levels and insulin resistance.[57]
  • Improvement in cardiovascular health and all cause mortality

Exercise

  • When combined with weight loss, superior to exercise or weight loss alone[58]


Oral Medications

Acetaminophen

  • Cochrane review: Superior to placebo for pain relief[59]
  • Similar to placebo for physical function, stiffness
  • NNT 4-16, fewer GI side effects than NSAIDS

NSAIDS

  • Considered superior to Acetaminophen for pain relief
  • Also helps with stiffness, global function, physical function
  • Patients should be made aware of gastrointestinal, renal and cardiovascular risks
    • For people with adverse GI side effects, adding a PPI can help relieve symptoms[60]
  • This class of medications is contraindicated in some patients

Opioids

  • Should only be prescribed when non-opioid medications fail to control pain
  • Prescribed at the lowest dose with careful monitoring
  • Strongly encouraged to involve pain management if patients on long term opioids

Doxycycline

  • Inhibits matrix metalloproteinases
  • Helped with joint space narrowing, no improvement in pain or function[61]
  • Benefits outweighed by adverse events

Bisphosphonates

  • General
    • Inhibition of osteoclast activity may reverse subchondral bone changes
  • Knee Osteoarthritis
    • In a small study, risedronate significantly reduced markers of cartilage degradation and bone resorption at 1 year follow up[62]
    • In a much larger study, risedronate (compared with placebo) did not improve signs or symptoms of OA, nor did it alter progression of OA, a reduction in the level of a marker of cartilage degradation was observed[63]
    • In a small study, zoledronic acid reduced knee pain, size of bone marrow lesions over 6 months[64]

Strontium Ranelate

  • General
    • Used for osteoporosis, stimulates calcium receptors and increases bone formation
    • Poorly researched for use in osteoarthritis
  • Knee Osteoarthritis
    • Treatment with strontium ranelate 1 and 2 g/day is associated with a significant effect on structure in patients with knee osteoarthritis, and a beneficial effect on symptoms for strontium ranelate 2 g/day.[65]

AMG 108

  • Is a mnoclonal antibody against the interleukin 1 receptor
  • Demonstrated statistically insignificant but numerically greater improvements in pain; however, minimal, if any, clinical benefit was observed.[66]

Adalimumab

  • General
    • Trade name is Humira
    • Is a monoclonal antibody to TNFα
  • Hand Osteoarthritis
    • No difference in disease progression between adalimumab and placebo at 12 months follow up[67]
  • Knee Osteoarthritis
    • This small, non-blinded study showed improvement in pain, stiffness, function and joint swelling at 12 weeks[68]

Tricyclic Antidepressants

  • Imipramine demonstrated no difference in pain when compared to placebo, however there was a slight improvement in grip strength[69]


Topical Medications

Capsaicin

  • Safe, well tolerated, no systemic toxicity
  • Application site burning pain peaks at one weak and resolves over time
  • Administered four times daily, capsaicin is moderately effective in reducing pain intensity up to 20 weeks regardless of site of application and dose in patients with at least moderate pain and clinical or radiologically defined OA, and is well tolerated.[70]

Topical NSAIDS

  • Recommended by governing bodies for hand and knee OA[71]
  • Topical and oral NSAIDs demonstrate an equivalent effect on knee pain over 1 year of treatment, with fewer adverse events due to lower systemic absorption of topical NSAIDs compared with oral NSAIDs[72]


Supplements

Chondroitin And Glucosamine

  • Demonstrate anti-inflammatory, anti-catabolic properties in vitro[73]
  • Overall literature, systematic reviews and governing bodies have not indicated any clinically relevant benefits[74]

Fish Oil

  • General
    • Used for a variety of ailments in addition to OA
    • Contains omega-3 polyunsaturated fatty acids
    • Anti-inflammatory and chondroprotective in animal studies
  • Hip/Knee OA
    • In a double blinded RCT, No benefit when added to glucosamine compared to placebo[75]

S-adenosylmethionine (SAMe)

  • Soeken et al meta-analysis: similar effect to NSAIDS in reducing pain, improving function with fewer adverse events[76]
  • Note, limited to only 2 studies

Methylsulfonylmethane (MSM)

  • Knee OA
    • When combined with glucosamine compared to glucosamine alone, there was increased efficacy in reducing pain and swelling and in improving the functional ability of joints than the individual agents[77]
    • Kim et al: randomized, double blinded RCT MSM twice a day improved symptoms of pain and physical function over the 12 week study period[78]

Collagen Hydrolysate

  • General
    • Collagen hydrolysate ingestion stimulates a statistically significant increase in synthesis of extracellular matrix macromolecules by chondrocytes[79]
  • Knee OA
    • Two small studies suggest that it helps with pain from knee OA[80][81]

Passion Fruit Peel Extract

  • Knee OA
    • In a small, randomized, double-blinded placebo controlled study, there was a statistically significant reduction in pain, stiffness, physical function and WOMAC score compared to placebo[82]

Curcuma Longa Extract

  • Knee OA
    • In this small, randomized, single blind, placebo-controlled trial of patients with primary knee OA, curcuma longa extract showed significant decrease knee pain[83]
    • Additionally shown to reduce serum levels of inflammatory markers IL-1, malondialdehyde[84]

Boswellia Serrata Extract (BSE)

  • Knee OA
    • In a randomized double blind placebo controlled crossover study had statistically significant decrease in knee pain and swelling, increased flexion and walking[85]
    • BSE showed a slower onset of action but the effect persisted even after stopping therapy compared to valdecoxib[86]

Curcumin

  • General
    • In patients with undefined arthritis, a brand-name formulation succesfully improved WOMAC score, walking distance and decreased CRP[87]

Pine Bark Extract

  • General
    • Brand name Pycnogenol
    • Exerts antioxidative, anti-inflammatory, and chondroprotective effects in vitro and in vivo
    • Provides long-lasting positive effects such as enhanced physical mobility and pain relief for patients with mild OA[88]
  • Knee OA
    • In 100 patients with knee OA randomized to pine bark extract or placebo, pations reported inmproved WOMAC score and alleviation of pain compared to placebo[89]

L-Carnitine

  • Knee OA
    • In a randomized double-blind placebo-controlled trial trial of women with knee OA, Kolahij et al found 750 mg/day was superior to placebo for pain reduction, stiffness, physical function and WOMAC score[90]


Physical Therapy

General

  • Hip OA
    • Bennell et al found physical therapy did not result in greater improvement in pain or function compared with sham treatment[91]
  • Knee OA
    • Meta-Analysis (Want et al)[92]
      • Low-strength evidence that aerobic exercise, aquatic exercise improved disability
      • Aerobic exercise, strengthening exercise, and ultrasonography reduced pain and improved function
      • Short- but not long-term follow-up proprioception exercise reduced pain and Tai Chi improved function.

Low Level Laser Therapy (LLLT)

  • Knee OA
    • When combined with exercise, effective in yielding pain relief, function and activity compared to placebo[93]


Complementary and Alternative Medicine

Acupuncture

  • Chen et al: No improvement in symptoms when acupuncture was combined with physical therapy compared to physical therapy alone [94]


Intra-Articular Injections

Corticosteroid Injection

  • General
    • Intra-articular (IA) corticosteroid injections are commonly used for pain relief in primary and secondary care
  • Knee OA
    • The research evidence demonstrates that IA CS injections provide short term reduction in OA pain and can be considered as an adjunct to core treatment for the relief of moderate to severe pain in people with OA[95]
    • 2015 Cochrane review: suggested that effects decrease over time, and our analysis provided no evidence that an effect remains six months after a corticosteroid injection[96]

Dextrose Prolotherapy

  • General
    • Injection of dextrose into pathologic joint in order to generate an inflammatory process
    • Note: injectant can be substance other than dextrose, however dextrose most common
  • Knee OA
    • Rahimzadeh et al found that prolotherapy decreased WOMAC scores. Note they also found PRP to be superior to prolotherapy [97]
    • 3 Arm study: Dextrose prolotherapy resulted in clinically meaningful sustained improvement of pain, function, and stiffness scores for knee osteoarthritis compared with blinded saline injections and at-home exercises[98]

Viscosupplementation

  • General
    • Hyaluronic acid is a naturally ocurring glycosaminoglycan (GAG) found in synovial fluid that can acts as a lubricant
    • Sometimes referred to as visco, viscosupplementation, or rooster comb
  • Knee Osteoarthritis
    • 2012 meta-analysis:No clinically relevant benefit for pain relief[99]
    • Subsequently has fallen out of favor but still a non-surgical option

Lubricin

  • General
    • Glycoprotein that acts synergistically with Hyaluronic acid
    • Minimal research at this time, however offers therapeutic potential
    • Supplementation restores normal joint lubrication and might be chondroprotective[100][101]

Anakinra

  • General
    • Recombinant antagonist of interleukin-1 receptor
  • Knee OA
    • Anakinra was well tolerated as a single 50‐mg or 150‐mg intraarticular injection in patients with OA of the knee.
    • However, anakinra was not associated with improvements in OA symptoms compared with placebo.[102]

Sprifermin

  • General
    • also known as recombinant human fibroblast growth factor 18 (rhFGF18)
  • Knee OA
    • Intra-articular administration of 100 μg of sprifermin every 6 or 12 months vs placebo resulted in an improvement in total femorotibial joint cartilage thickness after 2 years that was statistically significant, but of uncertain clinical importance[103]


Regenerative Medicine

Stem Cell Therapy

  • General
    • Poorly understood and studied

Platelet Rich Plasma

  • Knee OA
    • Systematic review: PRP injection results in significant clinical improvements up to 12 months postinjection. Clinical outcomes and WOMAC scores are significantly better after PRP versus HA at 3 to 12 months postinjection.[104]

Dextrose Prolotherapy

  • General
    • Injection of dextrose into pathologic joint in order to generate an inflammatory process
    • Note: injectant can be substance other than dextrose, however dextrose most common
  • Knee OA
    • Rahimzadeh et al found that prolotherapy decreased WOMAC scores. Note they also found PRP to be superior to prolotherapy [105]
    • 3 Arm study: Dextrose prolotherapy resulted in clinically meaningful sustained improvement of pain, function, and stiffness scores for knee osteoarthritis compared with blinded saline injections and at-home exercises[106]


Surgery

Periarticular Osteotomy

  • Knee Osteoarthritis
    • Osteotomy to correct the mechanical axis of the knee show promise have shown symptomatic improvement extending beyond 10 years[107]

Debridement of Lesions

  • Hip Osteoarthritis
    • Recontour femur has been shown to reduce risk of FAI and modify long-term risk of osteoarthritis[108]

Joint Distraction

  • Knee Osteoarthritis
    • Temporary surgical joint distraction produced symptomatic and structural improvement in end-stage knee osteoarthritis[109]

Cartilage Lesions

  • Autologous Cartilage Transplant
  • Osteochondral Graftin
  • Microfracture

Arthroplasty

  • Definitive Management for patients refractory to conservative management and who are not candidates for less invasive surgery

Return to Play


Complications

  • Need for surgery
  • Chronic pain
  • Functional
    • Loss of ADLs
    • Physical inactivity
    • Decreased physical activity
  • Slightly increased risk of
    • Cardiovascular disease[110]
    • Atherosclerotic-related disease[111]
  • Psychiatric
    • Depression due to chronic pain[112]

See Also


References


  1. Kellgren J, Lawrence JIn: Atlas of standard radiographs. The epidemiology of chronic rheumatism, vol. 2. Oxford (UK): Blackwell Scientific Publications; 1963.
  2. Hannan MT, Felson DT, Pincus T. Analysis of the discordance between radiographic changes and knee pain in osteoarthritis of the knee. J Rheumatol 2000;27(6):1513–7
  3. Murphy L, Schwartz TA, Helmick CG, et al. Lifetime risk of symptomatic knee osteoarthritis. Arthritis Rheum 2008;59(9):1207–13
  4. James, Spencer L., et al. "Global, regional, and national incidence, prevalence, and years lived with disability for 354 diseases and injuries for 195 countries and territories, 1990–2017: a systematic analysis for the Global Burden of Disease Study 2017." The Lancet 392.10159 (2018): 1789-1858.
  5. Woolf AD, Pfl eger B. Burden of major musculoskeletal conditions. Bull World Health Organ 2003; 81: 646–56
  6. Lawrence RC, Felson DT, Helmick CG, et al. Estimates of the prevalence of arthritis and other rheumatic conditions in the United States. Part II. Arthritis Rheum 2008;58(1):26–35.
  7. Oliveria SA, Felson DT, Reed JI, et al. Incidence of symptomatic hand, hip, and knee osteoarthritis among patients in a health maintenance organization. Arthritis Rheum 1995;38(8):1134–41.
  8. Hiligsmann M, Cooper C, Arden N, et al. Health economics in the field of osteoarthritis: an expert’s consensus paper from the European Society for Clinical and Economic Aspects of Osteoporosis and Osteoarthritis (ESCEO). Semin Arthritis Rheum 2013; 43: 303–13.
  9. Centers for Disease Control and Prevention (CDC): Prevalence of disabilities and associated health conditions among adults—United States, 1999. MMWR Morb Mortal Wkly Rep 2001;50(7):120-125.
  10. Hootman JM, Helmick CG: Projections of US prevalence of arthritis and associated activity limitations. Arthritis Rheum 2006;54(1):226-229.
  11. American Academy of Orthopaedic Surgeons: Arthritis and related conditions, in Jacobs JJ: The Burden of Musculoskeletal Diseases in the United States: Prevalence, Societal and Economic Cost. Rosemont, IL, American Academy of Orthopaedic Surgeons, 2008.
  12. Liu-Bryan R, Terkeltaub R. Chondrocyte innate immune myeloid differentiation factor 88-dependent signaling drives procatabolic effects of the endogenous Toll-like receptor 2/Toll-like receptor 4 ligands low molecular weight hyaluronan and high mobility group box chromosomal protein 1 in mice. Arthritis Rheum 2010; 62: 2004–12
  13. Sanchez, Christelle, et al. "Regulation of subchondral bone osteoblast metabolism by cyclic compression." Arthritis & Rheumatism 64.4 (2012): 1193-1203.
  14. Weinans, H., et al. "Pathophysiology of peri-articular bone changes in osteoarthritis." Bone 51.2 (2012): 190-196.
  15. Taljanovic, Mihra S., et al. "Bone marrow edema pattern in advanced hip osteoarthritis: quantitative assessment with magnetic resonance imaging and correlation with clinical examination, radiographic findings, and histopathology." Skeletal radiology 37.5 (2008): 423-431.
  16. Buckland-Wright, Christopher. "Subchondral bone changes in hand and knee osteoarthritis detected by radiography." Osteoarthritis and cartilage 12 (2004): 10-19.
  17. Glyn-Jones, Sion, et al. "Osteoarthritis." The Lancet 386.9991 (2015): 376-387.
  18. Bastow, E. R., et al. "Hyaluronan synthesis and degradation in cartilage and bone." Cellular and Molecular Life Sciences 65.3 (2008): 395-413.
  19. Bastow, E. R., et al. "Hyaluronan synthesis and degradation in cartilage and bone." Cellular and Molecular Life Sciences 65.3 (2008): 395-413.
  20. Jin, Xingzhong, et al. "Circulating C reactive protein in osteoarthritis: a systematic review and meta-analysis." Annals of the rheumatic diseases 74.4 (2015): 703-710.
  21. Lawrence RC, Felson DT, Helmick CG, et al, and the National Arthritis Data Workgroup. Estimates of the prevalence of arthritis and other rheumatic conditions in the United States. Part II. Arthritis Rheum 2008; 58: 26–35
  22. Srikanth VK, Fryer JL, Zhai G, et al. A meta-analysis of sex differences prevalence, incidence and severity of osteoarthritis. Osteoarthritis Cartilage 2005; 13(9):769–81.
  23. Wluka AE, Cicuttini FM, Spector TD. Menopause, oestrogens and arthritis. Maturitas 2000;35(3):183–99.
  24. Nevitt MC, Xu L, Zhang YQ, et al. Very low prevalence of hip osteoarthritis among Chinese elderly in Beijing compared to Caucasians in the U.S.: the Beijing Osteoarthritis Study. Arthritis Rheum 2002;46(7):1773–9.
  25. Nelson E, Braga L, Benner J, et al. Characterization of individual radiographic features of hip osteoarthritis in African American and White women and men: the Johnston County Osteoarthritis Project. Arthritis Care Res (Hoboken) 2010;62(2):190–7.
  26. Spector TD, Cicuttini F, Baker J, et al. Genetic influences on osteoarthritis in women: a twin study. BMJ 1996;312(7036):940–3.
  27. Roos EM, Ostenberg A, Roos H, et al. Long-term outcome of meniscectomy: symptoms, function, and performance tests in patients with or without radiographic osteoarthritis compared to matched controls. Osteoarthritis Cartilage 2001;9(4):316–24.
  28. Lohmander LS, Ostenberg A, Englund M, et al. High prevalence of knee osteoarthritis, pain, and functional limitations in female soccer players twelve years after anterior cruciate ligament injury. Arthritis Rheum 2004;50(10):3145–52.
  29. McAlindon TE, Wilson PW, Aliabadi P, et al. Level of physical activity and the risk of radiographic and symptomatic knee osteoarthritis in the elderly: the Framingham Study. Am J Med 1999;106(2):151–7
  30. Lane NE, Hochberg MC, Pressman A, et al. Recreational physical activity and the risk of osteoarthritis of the hip in elderly women. J Rheumatol 1999;26(4): 849–54.
  31. Puranen J, Ala-Ketola L, Peltokallio P, et al. Running and primary osteoarthritis of the hip. Br Med J 1975;2(5968):424–5.
  32. Kujala UM, Kettunen J, Paananen H, et al. Knee osteoarthritis in former runners, soccer players, weight lifters, and shooters. Arthritis Rheum 1995;38(4):539–46.
  33. Roos H, Lindberg H, Gardsell P, et al. The prevalence of gonarthrosis and its relation to meniscectomy in former soccer players. Am J Sports Med 1994; 22(2):219–22.
  34. Felson DT, Lawrence RC, Dieppe PA, et al. Osteoarthritis: new insights. Part 1: the disease and its risk factors. Ann Intern Med 2000;133(8):635–46.
  35. Felson DT, Zhang Y, Anthony JM, et al. Weight loss reduces the risk for symptomatic knee osteoarthritis in women. The Framingham Study. Ann Intern Med 1992;116(7):535–9.
  36. McAlindon TE, Felson DT, Zhang Y, et al. Relation of dietary intake and serum levels of vitamin D to progression of osteoarthritis of the knee among participants in the Framingham Study. Ann Intern Med 1996;125(5):353–9.
  37. Lane NE, Gore LR, Cummings SR, et al. Serum vitamin D levels and incident changes of radiographic hip osteoarthritis: a longitudinal study. Study Epidemiology of Osteoarthritis 365 of Osteoporotic Fractures Research Group. Arthritis Rheum 1999;42(5): 854–60.
  38. Felson DT, Niu J, Clancy M, et al. Low levels of vitamin D and worsening of knee osteoarthritis: results of two longitudinal studies. Arthritis Rheum 2007;56(1): 129–36
  39. McAlindon TE, Jacques P, Zhang Y, et al. Do antioxidant micronutrients protect against the development and progression of knee osteoarthritis? Arthritis Rheum 1996;39(4):648–56.
  40. Wluka AE, Stuckey S, Brand C, et al. Supplementary vitamin E does not affect the loss of cartilage volume in knee osteoarthritis: a 2 year double blind randomized placebo controlled study. J Rheumatol 2002;29(12):2585–91.
  41. Sasaki S, Iwata H, Ishiguro N, et al. Low-selenium diet, bone, and articular cartilage in rats. Nutrition 1994;10(6):538–43
  42. Moreno-Reyes R, Mathieu F, Boelaert M, et al. Selenium and iodine supplementation of rural Tibetan children affected by Kashin-Beck osteoarthropathy. Am J Clin Nutr 2003;78(1):137–44.
  43. Engstrom G, De Verdier MG, Nilsson PM, et al. Incidence of severe knee and hip osteoarthritis in relation to dietary intake of antioxidants beta-carotene, vitamin C, vitamin E and selenium: a population-based prospective cohort study. Arthritis Rheum 2009;60:s235–6.
  44. Neogi T, Booth SL, Zhang YQ, et al. Low vitamin K status is associated with osteoarthritis in the hand and knee. Arthritis Rheum 2006;54(4):1255–61.
  45. Dominick KL, Jordan JM, Renner JB, et al. Relationship of radiographic and clinical variables to pinch and grip strength among individuals with osteoarthritis. Arthritis Rheum 2005;52(5):1424–30.
  46. Chaisson CE, Zhang Y, Sharma L, et al. Grip strength and the risk of developing radiographic hand osteoarthritis: results from the Framingham Study. Arthritis Rheum 1999;42(1):33–8.
  47. Stulberg SD, Cooperman DR, Wallensten R. The natural history of Legg-CalvePerthes disease. J Bone Joint Surg Am 1981;63(7):1095–108.
  48. Sharma L, Chmiel JS, Almagor O, et al. The role of varus and valgus alignment in the initial development of knee cartilage damage by MRI: the MOST study. Ann Rheum Dis 2013; 72: 235–40.
  49. Golightly YM, Allen KD, Renner JB, et al. Relationship of limb length inequality with radiographic knee and hip osteoarthritis. Osteoarthritis Cartilage 2007; 15(7):824–9.
  50. Slemenda C, Brandt KD, Heilman DK, et al. Quadriceps weakness and osteoarthritis of the knee. Ann Intern Med 1997;127(2):97–104.
  51. Gossec, L., et al. "Comparative evaluation of three semi-quantitative radiographic grading techniques for hip osteoarthritis in terms of validity and reproducibility in 1404 radiographs: report of the OARSI-OMERACT Task Force." Osteoarthritis and cartilage 17.2 (2009): 182-187.
  52. Guermazi, Ali, et al. "Prevalence of abnormalities in knees detected by MRI in adults without knee osteoarthritis: population based observational study (Framingham Osteoarthritis Study)." Bmj 345 (2012): e5339.
  53. Eckstein, Felix, et al. "How do short-term rates of femorotibial cartilage change compare to long-term changes? Four year follow-up data from the osteoarthritis initiative." Osteoarthritis and cartilage 20.11 (2012): 1250-1257.
  54. Keen, H. I., R. J. Wakefield, and P. G. Conaghan. "A systematic review of ultrasonography in osteoarthritis." Annals of the rheumatic diseases 68.5 (2009): 611-619.
  55. Felson, David T., et al. "Weight loss reduces the risk for symptomatic knee osteoarthritis in women: the Framingham Study." Annals of internal medicine 116.7 (1992): 535-539.
  56. Gudbergsen, H., et al. "Weight loss is effective for symptomatic relief in obese subjects with knee osteoarthritis independently of joint damage severity assessed by high-field MRI and radiography." Osteoarthritis and cartilage 20.6 (2012): 495-502.
  57. Richette, Pascal, et al. "Benefits of massive weight loss on symptoms, systemic inflammation and cartilage turnover in obese patients with knee osteoarthritis." Annals of the rheumatic diseases 70.1 (2011): 139-144.
  58. Messier SP, Loeser RF, Miller GD, et al. Exercise and dietary weight loss in overweight and obese older adults with knee osteoarthritis: the Arthritis, Diet, and Activity Promotion Trial. Arthritis Rheum 2004;50(5):1501–10.
  59. Towheed, Tanveer, et al. "Acetaminophen for osteoarthritis." Cochrane Database of Systematic Reviews 1 (2006).
  60. Scheiman JM, Yeomans ND, Talley NJ, Vakil N, Chan FK, Tulassay Z, Rainoldi JL, Szczepanski L, Ung KA, Kleczkowski D, Ahlbom H, Naesdal J, Hawkey C. Prevention of ulcers by esomeprazole in at-risk patients using non-selective NSAIDs and COX-2 inhibitors. Am J Gastroenterol. 2006 Apr;101(4):701-10. Epub 2006 Feb 22. PubMed PMID: 16494585
  61. da Costa, Bruno R., et al. "Doxycycline for osteoarthritis of the knee or hip." Cochrane Database of Systematic Reviews 11 (2012).
  62. Spector, Tim D., et al. "Effect of risedronate on joint structure and symptoms of knee osteoarthritis: results of the BRISK randomized, controlled trial [ISRCTN01928173]." Arthritis research & therapy 7.3 (2005): R625.
  63. Bingham III, Clifton O., et al. "Risedronate decreases biochemical markers of cartilage degradation but does not decrease symptoms or slow radiographic progression in patients with medial compartment osteoarthritis of the knee: results of the two‐year multinational knee osteoarthritis structural arthritis study." Arthritis & Rheumatism: Official Journal of the American College of Rheumatology 54.11 (2006): 3494-3507.
  64. Laslett, Laura Louise, et al. "Zoledronic acid reduces knee pain and bone marrow lesions over 1 year: a randomised controlled trial." Annals of the rheumatic diseases 71.8 (2012): 1322-1328.
  65. Reginster, Jean-Yves, et al. "Efficacy and safety of strontium ranelate in the treatment of knee osteoarthritis: results of a double-blind, randomised placebo-controlled trial." Annals of the rheumatic diseases 72.2 (2013): 179-186.
  66. Cohen, Stanley B., et al. "A randomized, double-blind study of AMG 108 (a fully human monoclonal antibody to IL-1R1) in patients with osteoarthritis of the knee." Arthritis research & therapy 13.4 (2011): R125.
  67. Verbruggen, Gust, et al. "Tumour necrosis factor blockade for the treatment of erosive osteoarthritis of the interphalangeal finger joints: a double blind, randomised trial on structure modification." Annals of the rheumatic diseases 71.6 (2012): 891-898.
  68. Maksymowych, Walter P., et al. "Targeting tumour necrosis factor alleviates signs and symptoms of inflammatory osteoarthritis of the knee." Arthritis research & therapy 14.5 (2012): R206.
  69. Scott WA. The relief of pain with an antidepressant in arthritis. Practitioner. 1969; 202(212):802-807
  70. Laslett, Laura L., and Graeme Jones. "Capsaicin for osteoarthritis pain." Capsaicin as a Therapeutic Molecule. Springer, Basel, 2014. 277-291.
  71. Hochberg, Marc C., et al. "American College of Rheumatology 2012 recommendations for the use of nonpharmacologic and pharmacologic therapies in osteoarthritis of the hand, hip, and knee." Arthritis care & research 64.4 (2012): 465-474.
  72. Rannou, François, Jean-Pierre Pelletier, and Johanne Martel-Pelletier. "Efficacy and safety of topical NSAIDs in the management of osteoarthritis: Evidence from real-life setting trials and surveys." Seminars in arthritis and rheumatism. Vol. 45. No. 4. WB Saunders, 2016.
  73. Henrotin, Yves, and Cécile Lambert. "Chondroitin and glucosamine in the management of osteoarthritis: an update." Current rheumatology reports 15.10 (2013): 361.
  74. McAlindon, Timothy E., et al. "OARSI guidelines for the non-surgical management of knee osteoarthritis." Osteoarthritis and cartilage 22.3 (2014): 363-388.
  75. Gruenwald, Joerg, et al. "Effect of glucosamine sulfate with or without omega-3 fatty acids in patients with osteoarthritis." Advances in therapy 26.9 (2009): 858.
  76. Soeken, Karen L., et al. "Safety and efficacy of S-adenosylmethionine (SAMe) for osteoarthritis." J Fam Pract 51.5 (2002): 425-30.
  77. Usha, P. R., and M. U. R. Naidu. "Randomised, double-blind, parallel, placebo-controlled study of oral glucosamine, methylsulfonylmethane and their combination in osteoarthritis." Clinical drug investigation 24.6 (2004): 353-363.
  78. Kim, Linda S., et al. "Efficacy of methylsulfonylmethane (MSM) in osteoarthritis pain of the knee: a pilot clinical trial." Osteoarthritis and Cartilage 14.3 (2006): 286-294.
  79. Bello, Alfonso E., and Steffen Oesser. "Collagen hydrolysate for the treatment of osteoarthritis and other joint disorders: a review of the literature." Current medical research and opinion 22.11 (2006): 2221-2232.
  80. Benito-Ruiz P, Camacho-Zambrano MM, Carrillo-Arcentales JN, et al. A randomized controlled trial on the efficacy and safety of a food ingredient, collagen hydrolysate, for improving joint comfort. Int J Food Sci Nutr. 2009;60 Suppl 2:99-113. doi: 10.1080/09637480802498820. Epub 2009 Feb 11. PubMed PMID: 19212858.
  81. Crowley DC, Lau FC, Sharma P, et al. Safety and efficacy of undenatured type II collagen in the treatment of osteoarthritis of the knee: a clinical trial. Int J Med Sci. 2009 Oct 9;6(6):312-21. PubMed PMID: 19847319; PubMed Central PMCID: PMC2764342.
  82. Farid, Reza, et al. "Oral intake of purple passion fruit peel extract reduces pain and stiffness and improves physical function in adult patients with knee osteoarthritis." Nutrition research 30.9 (2010): 601-606.
  83. Madhu, K., K. Chanda, and M. J. Saji. "Safety and efficacy of Curcuma longa extract in the treatment of painful knee osteoarthritis: a randomized placebo-controlled trial." Inflammopharmacology 21.2 (2013): 129-136.
  84. Srivastava, Shobhit, et al. "Curcuma longa extract reduces inflammatory and oxidative stress biomarkers in osteoarthritis of knee: a four-month, double-blind, randomized, placebo-controlled trial." Inflammopharmacology 24.6 (2016): 377-388.
  85. Kimmatkar, N., et al. "Efficacy and tolerability of Boswellia serrata extract in treatment of osteoarthritis of knee–a randomized double blind placebo controlled trial." Phytomedicine 10.1 (2003): 3-7.
  86. Sontakke, S., et al. "Open, randomized, controlled clinical trial of Boswellia serrata extract as compared to valdecoxib in osteoarthritis of knee." Indian Journal of Pharmacology 39.1 (2007): 27.
  87. Belcaro G, Cesarone MR, Dugall M, et al. Product-evaluation registry of Meriva®, a curcumin-phosphatidylcholine complex, for the complementary management of osteoarthritis. Panminerva Med. 2010 Jun;52(2 Suppl 1):55-62. PubMed PMID:20657536.
  88. Rohdewald, Peter Jörg. "Review on sustained relief of osteoarthritis symptoms with a proprietary extract from pine bark, Pycnogenol." Journal of medicinal food 21.1 (2018): 1-4.
  89. Cisár, Peter, et al. "Effect of pine bark extract (Pycnogenol®) on symptoms of knee osteoarthritis." Phytotherapy Research 22.8 (2008): 1087-1092.
  90. Kolahi, Sousan, et al. "Effect of l-carnitine supplementation on clinical symptoms in women with osteoarthritis of the knee: A randomized, double-blind, placebo-controlled trial." European Journal of Integrative Medicine 7.5 (2015): 540-546.
  91. Bennell, Kim L., et al. "Effect of physical therapy on pain and function in patients with hip osteoarthritis: a randomized clinical trial." Jama 311.19 (2014): 1987-1997.
  92. Wang, Shi-Yi, et al. "Physical therapy interventions for knee pain secondary to osteoarthritis: a systematic review." Annals of internal medicine 157.9 (2012): 632-644.
  93. Alfredo, Patrícia Pereira, et al. "Efficacy of low level laser therapy associated with exercises in knee osteoarthritis: a randomized double-blind study." Clinical rehabilitation 26.6 (2012): 523-533.
  94. Chen, Lan X., et al. "Integrating acupuncture with exercise-based physical therapy for knee osteoarthritis: a randomized controlled trial." Journal of clinical rheumatology: practical reports on rheumatic & musculoskeletal diseases 19.6 (2013): 308.
  95. National Collaborating Centre for Chronic Conditions (UK) Osteoarthritis: National clinical guideline for care and management in adults. London: Royal College of Physicians (UK); 2008.
  96. Jüni, Peter, et al. "Intra‐articular corticosteroid for knee osteoarthritis." Cochrane Database of Systematic Reviews 10 (2015).
  97. Rahimzadeh et al. The effects of injecting intrarticular platelet-rich plasma or prolotherapy on pain score and function in knee osteoarthritis. Clinical Interventions in Aging. 2018: 13; 73-79.
  98. Rabago, David, et al. "Dextrose prolotherapy for knee osteoarthritis: a randomized controlled trial." The Annals of Family Medicine 11.3 (2013): 229-237.
  99. Rutjes, Anne WS, et al. "Viscosupplementation for osteoarthritis of the knee: a systematic review and meta-analysis." Annals of internal medicine 157.3 (2012): 180-191.
  100. Ludwig, Taryn E., et al. "Diminished cartilage‐lubricating ability of human osteoarthritic synovial fluid deficient in proteoglycan 4: Restoration through proteoglycan 4 supplementation." Arthritis & Rheumatism 64.12 (2012): 3963-3971.
  101. Ruan, Merry ZC, et al. "Proteoglycan 4 expression protects against the development of osteoarthritis." Science translational medicine 5.176 (2013): 176ra34-176ra34.
  102. Chevalier, X., et al. "Intraarticular injection of anakinra in osteoarthritis of the knee: a multicenter, randomized, double‐blind, placebo‐controlled study." Arthritis Care & Research 61.3 (2009): 344-352.
  103. Hochberg MC, Guermazi A, Guehring H, et al. Effect of Intra-Articular Sprifermin vs Placebo on Femorotibial Joint Cartilage Thickness in Patients With Osteoarthritis: The FORWARD Randomized Clinical Trial. JAMA. 2019;322(14):1360–1370. doi:10.1001/jama.2019.14735
  104. Meheux, Carlos J., et al. "Efficacy of intra-articular platelet-rich plasma injections in knee osteoarthritis: a systematic review." Arthroscopy: The Journal of Arthroscopic & Related Surgery 32.3 (2016): 495-505.
  105. Rahimzadeh et al. The effects of injecting intrarticular platelet-rich plasma or prolotherapy on pain score and function in knee osteoarthritis. Clinical Interventions in Aging. 2018: 13; 73-79.
  106. Rabago, David, et al. "Dextrose prolotherapy for knee osteoarthritis: a randomized controlled trial." The Annals of Family Medicine 11.3 (2013): 229-237.
  107. Spahn, Gunter, et al. "The impact of a high tibial valgus osteotomy and unicondylar medial arthroplasty on the treatment for knee osteoarthritis: a meta-analysis." Knee surgery, sports traumatology, arthroscopy 21.1 (2013): 96-112.
  108. Clohisy, John C., Lauren C. St John, and Amanda L. Schutz. "Surgical treatment of femoroacetabular impingement: a systematic review of the literature." Clinical Orthopaedics and Related Research® 468.2 (2010): 555-564.
  109. Wiegant, K., et al. "Sustained clinical and structural benefit after joint distraction in the treatment of severe knee osteoarthritis." Osteoarthritis and cartilage 21.11 (2013): 1660-1667.
  110. Wang H., Bai J., He B., Hu X., Liu D. Osteoarthritis and the risk of cardiovascular disease: A meta-analysis of observational studies. Sci. Rep. 2016;6:1–7.
  111. Veronese N., Cereda E., Maggi S., Luchini C., Solmi M., Smith T., Denkinger M., Hurley M., Thompson T., Manzato E., et al. Osteoarthritis and mortality: A prospective cohort study and systematic review with meta-analysis. Semin. Arthritis Rheum. 2016;46:160–167.
  112. Vina E.R., Kwoh C.K. Epidemiology of osteoarthritis. Curr. Opin. Rheumatol. 2018;30:160–167.
Created by:
John Kiel on 14 June 2019 08:15:47
Authors:
Last edited:
3 January 2021 15:07:34
Categories: